Nuwellis announced the publication of new data demonstrating the potential value of the Aquadex SmartFlow system’s aquapheresis therapy when treating patients with fluid overload as a result of end-stage liver disease. The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation. “This study presents an exciting new market opportunity for Nuwellis, and we look forward to gathering additional data demonstrating how Aquadex can benefit these patients,” said Nestor Jaramillo, Jr., president and chief executive officer of Nuwellis. “Four and a half million adults in the U.S. have been diagnosed with liver disease.1 To date, there has been little to no clinical evidence gathered demonstrating the benefits of aquapheresis for patients with liver disease. This publication lays the foundation for a new clinical application already within our current labeling that requires no additional regulatory clearances from the FDA.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NUWE:
- New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
- Nuwellis files to sell units, no amount given
- Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
- Nuwellis gets FDA clearance for an additional specialty dELC